The global infectious disease rapid diagnostics devices market is experiencing robust expansion as timely disease detection becomes a global healthcare priority. Valued at US$ 9.7 billion in 2024, the market is projected to grow at a CAGR of 6.9% from 2025 to 2035, exceeding US$ 20.2 billion by 2035. The accelerating burden of infectious diseases and the need for immediate and decentralized testing are driving worldwide adoption of rapid diagnostic technologies.
Access key findings and insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86762
Growing Need for Early Detection and Pandemic Preparedness
Frequent outbreaks of emerging and re-emerging pathogens-including COVID-19,
influenza variants, HIV, tuberculosis, and viral hepatitis-have reinforced the
critical role of real-time diagnostics. Rapid tests enable early
identification, isolation, and treatment decisions, helping reduce disease
transmission and mortality.
Governments, global health organizations, and private sectors are heavily
investing in diagnostic innovation and pandemic preparedness infrastructure,
creating strong, sustained market opportunities.
Shift Toward Point-of-Care and Home-Based Testing
Technological advancements have significantly improved the accuracy,
portability, and ease of use of rapid diagnostic devices. The growing adoption
of point-of-care (POC) and at-home test kits allows healthcare providers and
consumers to make quick decisions without waiting for centralized lab results.
Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/infectious-disease-rapid-diagnostics-devices-market.html
Competitive Landscape
The infectious disease rapid diagnostics devices market is highly competitive
and innovation-driven, with leading players focusing on molecular POC systems,
data connectivity, and expanded test menus.
Prominent companies include:
F. Hoffmann-La Roche AG
Abbott
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company (BD)
bioMérieux SA
Diasorin S.p.A.
Hologic, Inc.
QuidelOrtho Corporation
Siemens Healthineers AG
Seegene Inc.
QIAGEN
Danaher Corporation
Trinity Biotech
Grifols
These companies continue to expand through R&D investment, strategic
collaborations, and enhanced manufacturing capacities.
Regional Market Outlook
North America maintains a leading share due to advanced healthcare
infrastructure and high R&D investment.
Europe shows strong demand through national screening programs and public
health initiatives.
Asia-Pacific is the fastest-growing region, driven by rapid urbanization,
infectious disease prevalence, and expanding POC accessibility in India, China,
and Southeast Asia.
Africa and Latin America continue to receive major investments from global
health organizations for infectious disease control.
About Transparency Market Research
Transparency Market Research, a global market research company registered at
Wilmington, Delaware, United States, provides custom research and consulting
services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insights for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants use proprietary data
sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research
experts, so that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research employs
rigorous primary and secondary research techniques in developing distinctive
data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453